You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A Biodégradable and Biomimetic Xerogel for Periodontal Bone Regeneration

    SBC: INNOVATIVE RESEARCH SOLUTIONS INC            Topic: NIDCR

    DESCRIPTION provided by applicant Periodontal bone regeneration requires attention to a the need of a physical barrier to restrict the entry formation of fibro epithelial tissue b he cause of bone loss that is due to hostandapos s inflammatory response to pathological cause and not due to the causative pathogen directly so along with bone regeneration strategies the process also equally ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Abuse Deterrent Transdermal Drug Delivery System for Fentanyl

    SBC: BIONEX PHARMACEUTICALS LLC            Topic: NIDA

    Pain is the single greatest cause of disability and its management remains one of medicine s foremost challenges Potent opiates can effectively reduce the severity of pain thereby diminishing patient suffering Unfortunately chronic use of these drugs can be harmful to patients whether by inadvertent overdosing unintentional addiction or abuse resulting from dependency on the euphoric effec ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Combination Endovascular Device Therapeutic Hypothermia with Stentriever Devices

    SBC: Tom L Merrill            Topic: 106

    Project Summary Stroke is the th leading cause of death and number one cause of adult disability in the United States The primary goal of ischemic stroke treatment is quickly restoring blood perfusion However studies have shown that this return of blood flow while necessary can also cause damage to local tissue Hypothermia has been shown to decrease this reperfusion injury The overall go ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A COMMUNICATION AND CONTROL SYSTEM FOR THE MENTALLY RETARDED

    SBC: Scott Instruments Corp            Topic: N/A

    THE TOPIC OF THIS PROPOSAL IS THE DESIGN OF AN ENVIRONMENTALCONTROL SYSTEM FOR THE MORE THAN TWO MILLION INDIVIDUALS IN THE UNITED STATES WHOSE PHYSICAL AND/OR MENTAL IMPAIRMENTS ARE SO SEVERE THAT THEY ARE UNABLE TO FUNCTION IN THEIR ENVIRONMENT IN A NORMAL AND EFFECTIVE MANNER. A TWO-YEAR COLLABORATIVE RESEARCH EFFORT BETWEEN THE BIOENGINEERING PROGRAM AT THE NATIONAL HEADQUARTERS OF THE ASSOCIA ...

    SBIR Phase I 1987 Department of Health and Human Services
  6. A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention

    SBC: Genetic Networks, LLC            Topic: 100

    Project Summary This project proposes further development of a computational discovery platform shown to quantifiably identify and prioritize both targets and compounds for therapeutic intervention, which will accelerate the development of newer, more effective drugs with fewer side-effects. This platform is based on a novel fusion of two state of the art computational approaches (phenolog mapping ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction

    SBC: VASADE BIOSCIENCES, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT The most significant advance in the treatment of Myocardial Infarction (MI) has been reperfusion therapy, which must be applied immediately after the MI diagnosis has been made. Despite the thousands of studies on drug therapies designed to reduce the size of the MI, most have failed in clinical trials. Our hypothesis is that a major reason why these drugs failed is that t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A DIGITAL TELEMETRY MONITOR WITH MODULAR FEATURES

    SBC: United States Control            Topic: N/A

    N/A

    SBIR Phase I 1987 Department of Health and Human Services
  9. Advanced Cannula Development for Coronary Sinus Access

    SBC: STRATEGIC PACING SYSTEMS LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase STTR will develop novel techniques for coronary sinus access The coronary sinus provides unique anatomic and physiologic proximity to all four cardiac chambers and the coronary circulation For example the coronary sinus is used for left ventricular lead insertion for biventricular pacing or cardiac resynchronization Mor than such implan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Advanced CLAD PERG system with minimal patient preparation for clinical settings

    SBC: JORVEC CORP.            Topic: N

    AbstractGlaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cellsRGCdegenerationultimately manifesting in a functional loss of vision if left untreatedThere exist a number of therapeutic approaches to treat these conditionsbut there are currently no clinical methods to detect the onset of RGC dysfunctionThe Pattern ElectroretinogramPERGis the only established tool to ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government